The phase 3 KEYNOTE-062 trial compared pembrolizumab with or without chemotherapy versus chemotherapy for the first-line treatment of PD-L1+ (CPS ≥1) GC or gastroesophageal junction adenocarcinoma. This evidence concerns the gene CD274 and gastroesophageal junction adenocarcinoma.